Source comparison
MK-677 Dosage Protocol Guide: Research vs Clinical Comparison
Research (healthy subjects) 10–25mg daily Evening, fasted state 8–16 weeks Baseline + week 4, 8, 12 IGF-1; fasting glucose biweekly Gold standard for isolating compound effects. Strict controls, narrow dose range, short duration Clinical (GH deficiency) 25mg d
This comparison does not assign a generated winner or score.
- Research (healthy subjects)
- 10–25mg daily
- Evening, fasted state
- 8–16 weeks
- Baseline + week 4, 8, 12 IGF-1; fasting glucose biweekly
- Gold standard for isolating compound effects. Strict controls, narrow dose range, short duration
- Clinical (GH deficiency)
- 25mg daily
- Pre-sleep
- Continuous (>12 months)
- Monthly glucose, quarterly IGF-1, annual DEXA
- Therapeutic context allows higher sustained doses with medical supervision and metabolic support
- Extended research (aging)
- 12.5–25mg daily
- Evening
- 6–24 months
- Quarterly metabolic panel, semiannual body composition, sleep quality assessments
- Focuses on age-related GH decline. Lower doses, longer observation, emphasis on quality-of-life markers